Compare BioNano Genomics Inc (BNGO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Sony Group Corp — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Sony Group Corp trades at $23.16 (market cap $138.43B). The key difference: Sony Group Corp is far larger — about 10134× BioNano Genomics Inc's market cap, and Sony Group Corp pays a 0.67% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SONY | |
|---|---|---|
Market Cap | $13.66M | $138.43B |
Sector | Health | Technology |
52-Week High | $4.92 | $30.26 |
52-Week Low | $1.06 | $19.32 |
Enterprise Value | $16.26M | $136.35B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Sony's stock trades at $23.54, down 1.18% over 24 hours, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent earnings show mixed quarterly beats, with Q2 2026 EPS of $0.36 exceeding expectations. The company reported strong 2025 fundamentals, including $12.96T revenue and $1.14T net income, though 2026 projections indicate a net loss. Positive sentiment is driven by blockbuster film success, such as Spider-Man: Brand New Day, and a joint venture with TSMC for image sensors, highlighting growth in entertainment and technology segments.
Sony presents a favorable outlook with analyst consensus strongly bullish (68.75% buy ratings) and a potential 29.75% upside. Key opportunities include robust gaming and sensor divisions, but risks involve 2026 profit margin pressures, competitive threats, and execution challenges in new ventures. Investors should weigh solid cash flow and asset base against near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
